Heartwire - Episode 143: Dabigatran fatal bleeding less than in trials; obesity paradox in ACCOMPLISH; dulaglutide passes BP hurdle; DIG revisited: digoxin scrutinized anew; LDL-receptor mAb: more impressive data

Summary: For the week ending June 1, 2012 we discuss the following top cardiology news from heartwire: • Dabigatran fatal bleeding less than in clinical trials: New EMA data • Obesity paradox observed with hydrochlorothiazide, not amlodipine: ACCOMPLISH • Dulaglutide passes BP hurdle, but heart-rate increase observed • DIG revisited: Digoxin scrutinized anew for chronic heart failure • More impressive data with LDL-receptor mAb And also, in brief: • FDA panel recommends new studies of ASD occluders • Hope rekindled for ACE inhibitors, ARBs in preserved-EF heart failure • The future is now (sort of): Guidance on genetics and CVD from the AHA Join us for a comprehensive review of this week's most important cardiology news.